


PRODUCT INFORMATION



5-iodo A-85380 (hydrochloride)

Item No. 43194

CAS Registry No.: 1217837-17-6
Formal Name: 3-[(2S)-2-azetidylmethoxy]-5-iodo-pyridine, dihydrochloride
MF: C₉H₁₁IN₂O • 2HCl
FW: 363.0
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

5-iodo A-85380 (hydrochloride) is supplied as a solid. A stock solution may be made by dissolving the 5-iodo A-85380 (hydrochloride) in the solvent of choice, which should be purged with an inert gas. 5-iodo A-85380 (hydrochloride) is soluble (≥10 mg/ml) in DMSO and sparingly soluble (1-10 mg/ml) in ethanol.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of 5-iodo A-85380 (hydrochloride) can be prepared by directly dissolving the solid in aqueous buffers. 5-iodo A-85380 (hydrochloride) is soluble (≥10 mg/ml) in PBS (pH 7.2). We do not recommend storing the aqueous solution for more than one day.

Description

5-iodo A-85380 is an agonist of $\alpha 4\beta 2$ and $\alpha 6\beta 2$ subunit-containing nicotinic acetylcholine receptors (nAChRs).¹ It activates α -conotoxin MII-sensitive and -insensitive dopamine release in rat striatal synaptosomes, markers of $\alpha 4\beta 2$ and $\alpha 6\beta 2$ subunit-containing nAChR activation, respectively (EC_{50} s = 12.7 and ~35 nM, respectively). *In vivo*, 5-iodo A-85380 (0.37 μ mol/kg per day) decreases the total number of abnormal involuntary movements (AIMs) in a rat model of L-DOPA-induced Parkinson's disease.²

References

1. Mogg, A.J., Jones, F.A., Pullar, I.A., *et al.* Functional responses and subunit composition of presynaptic nicotinic receptor subtypes explored using the novel agonist 5-iodo-A-85380. *Neuropharmacology* **47(6)**, 848-859 (2004).
2. Huang, L.Z., Campos, C., Ly, J., *et al.* Nicotinic receptor agonists decrease L-dopa-induced dyskinesias most effectively in partially lesioned parkinsonian rats. *Neuropharmacology* **60(6)**, 861-861 (2011).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/30/2025

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM